TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02229149
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment for all patients will consist of trastuzumab, given as a loading dose of 8 mg/kg IV on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter.~Patients randomized to the chemotherapy plus trastuzumab arm (without pertuzumab) can receive trastuzumab 6 mg/kg IV every 3 weeks if they are receiving docetaxel or capecitabine on a 3-week cycle, or 4 mg/kg IV every 2 weeks if they are receiving vinorelbine, paclitaxel, or nab-paclitaxel on a 4-week cycle. The loading dose for all patients remains 8 mg/kg.~For patients randomized to the chemotherapy plus trastuzumab plus pertuzumab arm, both trastuzumab and pertuzumab need to be administered every 3 weeks regardless of which chemotherapy agent they are receiving.
Study: NCT02229149
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks.
Study: NCT02229149
Drug: Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: physician's choice of chemotherapy:~* Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~* Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~* Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~* Docetaxel 75 mg/m2 IV every 3 weeks; OR~* Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off.
Study: NCT03887377
Drug: Botulinum Toxins
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: We will be comparing botulinum toxin following breast reduction surgery to placebo injection. We will then compare photos of each breast reduction scar at set intervals following surgery.
Study: NCT01686503
Drug: IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depending on study arm, participants will receive 0.2 mL intradermally, 0.1 mL intradermally, 0.5 mL intramuscularly, or 0.2 mL intramuscularly.
Study: NCT02963077
Drug: A4250
Normalized name: Odevixibat
DrugBank: Odevixibat (DB16261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02963077
Drug: CRC (A3384)
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02963077
Drug: Questran
Normalized name: Questran
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04396886
Drug: Bintrafusp Alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa will be administered intravenously every 2 weeks
Study: NCT00919282
Drug: gemcitabine, folinic acid, 5-FU
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine 1g/m² - 30 minutes folinic acid 500mg/m² - 2 hours 5-FU 750mg/m² - over 24hours
Study: NCT01754714
Drug: SAMe 1000 mg
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner
Study: NCT01754714
Drug: SAMe 1500 mg
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner
Study: NCT01754714
Drug: SAMe 2000 mg
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner
Study: NCT04000165
Drug: AG-348
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a nonrandomized, intra-patient dose escalating clinical study. AG-348 will be administered starting at 5 mg twice a day, increasing to 20 mg twice a day, to maximum 50 mg or 100 mg twice a day. Dosing period is every 2 weeks at each dose level. Dose taper will start on Day 42 (50 mg) or Day 56 (100 mg) with dose reduced over 12 to 15 days.
Study: NCT04018027
Drug: difelikefalin 0.25 mg
DrugBank: Difelikefalin (DB11938)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral difelikefalin 0.25 mg administered twice daily
Study: NCT04018027
Drug: difelikefalin 0.5 mg
DrugBank: Difelikefalin (DB11938)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral difelikefalin 0.5 mg administered twice daily
Study: NCT04018027
Drug: difelikefalin 1.0 mg
DrugBank: Difelikefalin (DB11938)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral difelikefalin 1.0 mg administered twice daily
Study: NCT02024334
Drug: Leflunomide
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02989727
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine tablets at dosages of 25mg/day for Week 1 and Week 2, 50mg/day for Week 3 and Week 4, 100mg/day for Week 5, and 200mg/day for Week 6, Week 7, and Week 8.
Study: NCT00649519
Drug: Amlodipine and Benazepril HCl Capsules 10 mg/20 mg
Normalized name: benazepril and amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10/20mg, single dose fasting
Study: NCT01765764
Drug: bimatoprost solution
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost solution once a day or twice a day applied to each eyebrow for 7 months.
Study: NCT01765764
Drug: Vehicle to bimatoprost solution
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Vehicle to bimatoprost solution once or twice a day applied to each eyebrow for 7 months.
Study: NCT02242032
Drug: P-321 Ophthalmic Solution
Normalized name: p-hydroxyamphetamine / tropicamide Ophthalmic Solution [Paremyd]
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02242032
Drug: P-321 Ophthalmic Solution placebo
Normalized name: p-hydroxyamphetamine / tropicamide Ophthalmic Solution
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match P-321 Ophthalmic Solution
Study: NCT02333955
Drug: GCS-100
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg GCS-100 IV push. All doses of study drug will be administered least once monthly for a total of 1 year with a follow-up 4 weeks after the last dose is administered.
Study: NCT01177150
Drug: JNJ-28431754
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
Study: NCT00929578
Drug: Fluphenazine
Normalized name: Fluphenazine
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional injection of Fluphenazine
Study: NCT02307526
Drug: Pyridostigmine Bromide
Normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After being transferred onto a tilt table, subject will lie in a rested, supine position in which the study drug, pyridostigmine bromide will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
Study: NCT02343718
Drug: Vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02343718
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00991627
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg of a 5 mg/ml hyperbaric solution, intrathecally
Study: NCT00991627
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 µg of a 100 µg/ml solution, intrathecally
Study: NCT00991627
Drug: Lactated Ringer's solution
Normalized name: Lactated Ringer's Solution Intravenous Solution
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 ml/min intravenously
Study: NCT00991627
Drug: Atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 mg/kg iv bolus prn~Bradycardia defined as 50% drop in heart rate from baseline values.
Study: NCT00081289
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50mg/m\^2 IV over 1 hour on days 1, 8, 22, and 29
Study: NCT00081289
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50mg/m\^2 IV over 2 hours on days 1, 8, 15, 22, and 29
Study: NCT00081289
Drug: Folinic Acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m\^2 IV over 2 hours Day 1 (postoperatively) ,every 14 days, for nine 14-day cycles.
Study: NCT00081289
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m\^2 IV over 2 hours Day 1 (postoperatively), every 14 days, for nine 14-day cycles.
Study: NCT00916721
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
Study: NCT02354391
Drug: Ingenol mebutate Picato® and MAL PDT day 1, day 5
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment of ingenol mebutate, Picato® 0.015% topical gel applied on day 1 followed by MAL PDT on day 5
Study: NCT02354391
Drug: Ingenol mebutate Picato® day 2, 3, 4
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full treatment course with Ingenol mebutate (Picato®) 0.015% topical gel, apply day 2,3 and 4
Study: NCT02255591
Drug: Lidocaine-adrenaline added gadolinium.
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04331730
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept intravitreal injection
Study: NCT01466478
Drug: Ointment A: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily application, 4 weeks
Study: NCT03904576
Drug: BI 1358894
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT03987295
Drug: AL001
Normalized name: AL001
DrugBank: Latozinemab (DB16978)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg of AL001 every 4 weeks
Study: NCT01469052
Drug: AG-013736
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state
Study: NCT01469052
Drug: AG-013736
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib continuous oral dosing (20 mg twice a day) in the fed state
Study: NCT01469052
Drug: AG-013736
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib continuous oral dosing (5 mg twice a day) in the fed state
Study: NCT01469052
Drug: AG-013736
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib continuous oral dosing (15 mg once a day) in the fed state
Study: NCT01469052
Drug: AG-013736
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib continuous oral dosing (5 mg twice a day) in the fasted state
Study: NCT01469052
Drug: AG-013736
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state
Study: NCT02378428
Drug: MIBG
Normalized name: mIBG
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01359826
Drug: Milnacipran
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After dose escalations, patients will receive Milnacipran administered at 50 mg twice a day after for 12 weeks or milnacipran 50 mg twice day for 4 weeks and then 100 mg twice a day for an additional 6 weeks depending on tolerability and fatigue response.
Study: NCT03391440
Drug: morinidazole
Normalized name: Morinidazole
DrugBank: Morinidazole (DB15098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)
Study: NCT03334578
Drug: Gastrografin
Normalized name: Gastrografin
DrugBank: Diatrizoate (DB00271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gastrografin group
Study: NCT02145767
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01652378
Drug: ondansetron, lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron: Ondansetron (0.15 mg/kg) will be administered through the IV line over 15 min at a constant rate of infusion.~Lidocaine: Lidocaine will be administered as a 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg/kg/hour for 55 min (60 min total infusion).
Study: NCT01593748
Drug: Gemcitabine and Pazopanib
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.
Study: NCT01593748
Drug: Gemcitabine and Docetaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
Study: NCT02124850
Drug: Motolimod
Normalized name: Motolimod
DrugBank: Motolimod (DB12303)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02124850
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02124850
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02521376
Drug: Entospletinib
Normalized name: Entospletinib
DrugBank: Entospletinib (DB12121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entospletinib 100 mg tablet administered orally
Study: NCT00318201
Drug: Diltiazem
Normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00049413
Drug: pentostatin
Normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02468089
Drug: Carbepenem
Normalized name: Carbapenem
DrugBank: Carbapenem (DB18912)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02468089
Drug: Albumin
Normalized name: Albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00193362
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00193362
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00193362
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00193362
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01783522
Drug: glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months.
Study: NCT00381316
Drug: Technetium Tc99m Tetrofosmin injections
Normalized name: tetrofosmin
DrugBank: Tetrofosmin (DB11180)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single Isotope: be 555 to 888 MBq (15 to 24 mCi) MYOVIEW at Rest/i.v./bolus.
Study: NCT00381316
Drug: Thallous Chloride T1-201
DrugBank: Thallous chloride (DB09316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myoview SPECT Imaging
Study: NCT03729869
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg of exogenous progesterone twice a day
Study: NCT00883194
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution
Study: NCT02645747
Drug: Aflibercept (Eylea, BAY86-5321)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Eylea (intravitreal aflibercept) is an anti-Vascular Endothelial Growth Factor (VEGF) drug indicated for neovascular age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME) and visual impairment due to macular edema (ME) secondary to central or branched retinal vein occlusion (RVO).~RVO, both branch and central, is the second most common type of retinal vascular disorders after diabetic retinal disease. Central retinal vein occlusion (CRVO) is characterized by an obstruction of the central retinal vein combined with variable amounts of retinal arterial insufficiency.
Study: NCT01752569
Drug: Selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The treatment schedule requires selumetinib to be taken either once daily at the same time each day or twice daily approximately 12 hours apart. Selumetinib should be taken with water at least 2 hours after a meal and 1 hour before the next meal. Selumetinib capsules will be administered in a continuous 21 day cycle (6 cycles), unless disease progression occurs.~For phase I there were 4 potential dosing levels:~Level -1 - 50mg once daily (od) (50mg daily total)~Level 1 (starting dose level for phase I) - 50mg bi-daily (bd) (100mg daily total)~Level 2 - 75mg bd (150mg daily total)~Level 3 - 100mg bd (200mg daily total)~Phase I has been completed and identified 75mg bd as the recommended phase II dose.~Phase II has begun and is utilising a dose of 75mg bd of selumetinib.
Study: NCT01074411
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IP
Study: NCT01074411
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IP
Study: NCT02222727
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loading 20 mg dose of donepezil on first day of recruitment followed by once daily 5 mg dose for subsequent twenty days
Study: NCT02452970
Drug: RRx-001
Normalized name: RRx-001
DrugBank: RRx-001 (DB12060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRx-001 (10 mg/m2) intravenously twice weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 30 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
Study: NCT02452970
Drug: Gemcitabine and cisplatin
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
Study: NCT03630614
Drug: Electronic cigarette without nicotine (ECwN) plus active varenicline tablets
Normalized name: varenicline Oral Tablet
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The ECwN group use EC liquids containing 0 mg/mL of nicotine. Because nicotine delivery can be adjusted according to the user's need, all participants are able to adjust their individual nicotine dose by varying the wattage of their EC, by varying puff frequency and puff volume similarly as they are doing (or used to do) with conventional cigarettes.~EC device:~Mini iStick kit (20 W) Eleaf Clearomiser :GS Air M with resistance of 1.5 ohm, the clearomiser's Pyrex window is of blue colour not allowing to distinguish an eventual coloration of the e-liquid containing nicotine. Liquids for EC use are delivered in white opaque 10 mL vials not allowing to distinguish the color of the liquid.~Varenicline, Champix® 0.50 mg tablets Posology of vareniclin follows varenicline's monograph.
Study: NCT03630614
Drug: Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline
Normalized name: varenicline Oral Tablet
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The ECwoN group receives EC liquids with 0 mg/mL of nicotine on a double blind manner (in identical non-transparent refill bottles of 10 mL).~Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet. Posology of varenicline or its placebo follows varenicline's monograph.
Study: NCT03630614
Drug: Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline
Normalized name: varenicline Oral Tablet
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The ECwN group use EC liquids containing 12 mg/mL of nicotine. Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet. Posology of varenicline or its placebo follows varenicline's monograph.
Study: NCT00945750
Drug: Famotidine FCT
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Famotidine 20 mg oral film-coated tablet taken once daily
Study: NCT00945750
Drug: Famotidine CT
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Famotidine 20 mg oral chewable tablet taken once daily
Study: NCT00893113
Drug: Alfuzosin
Normalized name: Alfuzosin
DrugBank: Alfuzosin (DB00346)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg once daily
Study: NCT00293072
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes